Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Marcantonio

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Minerva Stomatologica|April 8, 2014
The influence of different implant surfaces on osseointegration in diabetes: a systematic review of the literatureL A Fontanari, G J Pimentel Lopes De Oliveira, T L Durigan Basso, et al.
International Journal of Oral and Maxillofacial Surgery|November 17, 2018
A randomized clinical trial evaluating maxillary sinus augmentation with different particle sizes of demineralized bovine bone mineral: histological and immunohistochemical analysisR S de Molon, F S Magalhaes-Tunes, C V Semedo, et al.
Journal of Clinical Pharmacology|November 15, 2017
Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot SamplingChi-Chung Li, Marissa Dockendorf, Ken Kowalski, et al.
Clinical and Translational Science|January 4, 2020
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult MalesWendy Ankrom, Phung Bondiskey, Chi-Chung Li, et al.
Clinical Pharmacology in Drug Development|January 21, 2026
A Human Mass Balance and Metabolism Study of [<sup>14</sup>C]-Ubrogepant in Healthy Male AdultsRamesh R Boinpally, Joshua Rowe, Pushpa Chandrasekar, et al.
Journal of Clinical Pharmacology|June 5, 2014
Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatibEugene E Marcantonio, Jeanine Ballard, Christopher R Gibson, et al.
Materials Science & Engineering. C, Materials for Biological Applications|June 6, 2015
Micro-arc oxidation as a tool to develop multifunctional calcium-rich surfaces for dental implant applicationsA R Ribeiro, F Oliveira, L C Boldrini, et al.
Eclinicalmedicine|February 6, 2024
Rycal S48168 (ARM210) for <i>RYR1</i>-related myopathies: a phase one, open-label, dose-escalation trialJoshua J Todd, Tokunbor A Lawal, Irene C Chrismer, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 27, 2013
In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232Eric D Hostetler, Aniket D Joshi, Sandra Sanabria-Bohórquez, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Minerva Stomatologica|April 8, 2014
The influence of different implant surfaces on osseointegration in diabetes: a systematic review of the literatureL A Fontanari, G J Pimentel Lopes De Oliveira, T L Durigan Basso, et al.
International Journal of Oral and Maxillofacial Surgery|November 17, 2018
A randomized clinical trial evaluating maxillary sinus augmentation with different particle sizes of demineralized bovine bone mineral: histological and immunohistochemical analysisR S de Molon, F S Magalhaes-Tunes, C V Semedo, et al.
Journal of Clinical Pharmacology|November 15, 2017
Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot SamplingChi-Chung Li, Marissa Dockendorf, Ken Kowalski, et al.
Clinical and Translational Science|January 4, 2020
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult MalesWendy Ankrom, Phung Bondiskey, Chi-Chung Li, et al.
Clinical Pharmacology in Drug Development|January 21, 2026
A Human Mass Balance and Metabolism Study of [<sup>14</sup>C]-Ubrogepant in Healthy Male AdultsRamesh R Boinpally, Joshua Rowe, Pushpa Chandrasekar, et al.
Journal of Clinical Pharmacology|June 5, 2014
Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatibEugene E Marcantonio, Jeanine Ballard, Christopher R Gibson, et al.
Materials Science & Engineering. C, Materials for Biological Applications|June 6, 2015
Micro-arc oxidation as a tool to develop multifunctional calcium-rich surfaces for dental implant applicationsA R Ribeiro, F Oliveira, L C Boldrini, et al.
Eclinicalmedicine|February 6, 2024
Rycal S48168 (ARM210) for <i>RYR1</i>-related myopathies: a phase one, open-label, dose-escalation trialJoshua J Todd, Tokunbor A Lawal, Irene C Chrismer, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 27, 2013
In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232Eric D Hostetler, Aniket D Joshi, Sandra Sanabria-Bohórquez, et al.
Pageof 9